


CXCR4 antagonist 7

Cat. No.:	HY-147808
CAS No.:	1185451-72-2
Molecular Formula:	C ₁₅ H ₁₇ N ₃ O ₃
Molecular Weight:	315.33
Target:	CXCR4; HIV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CXCR4 antagonist 7 (Compound PARA-B) is a CXCR4 antagonist with the IC ₅₀ of 9.3 nM. CXCR4 antagonist 7 can be used for the research of HIV infection, inflammatory diseases, cancer, and WHIM syndrome ^[1] .																
IC₅₀ & Target	CXCR4/CXCL12 9.3 nM (IC ₅₀)																
In Vitro	<p>CXCR4 antagonist 7 (PARA-B, 10 nM-1 μM, 20 h) inhibits CXCL12-induced GH4C1 cell proliferation with an IC₅₀ value of 9.3 nM^[1].</p> <p>CXCR4 antagonist 7 (1 μM, 12 h) inhibits CXCL12-dependent GH4C1 cell migration with inhibition rate of 50%^[1].</p> <p>CXCR4 antagonist 7 (50 nM, 30 min) reduces ERK1/2 phosphorylation induced by CXCL12^[1].</p> <p>CXCR4 antagonist 7 (50 nM-1 μM, 30 min) acts via CXCR4 antagonism to revert CXCL12 induction of GH4C1 proliferation and migration^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>GH4C1 cell (48 h of serum deprivation)</td> </tr> <tr> <td>Concentration:</td> <td>1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Had no effect on cell viability of GH4C1 cell.</td> </tr> </table> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>GH4C1 cell (FBS-starved GH4C1 cells treated with CXCL12 (25 nM) for 12 h)</td> </tr> <tr> <td>Concentration:</td> <td>10 nM-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>20 h, 24 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited proliferation of multiple cancer cell lines with IC₅₀ value ranging from 1.08 to 3.45 μM, and had no effect on cell viability of GH4C1 cell.</td> </tr> </table> <p>Cell Migration Assay^[1]</p>	Cell Line:	GH4C1 cell (48 h of serum deprivation)	Concentration:	1 μM	Incubation Time:	24 h	Result:	Had no effect on cell viability of GH4C1 cell.	Cell Line:	GH4C1 cell (FBS-starved GH4C1 cells treated with CXCL12 (25 nM) for 12 h)	Concentration:	10 nM-1 μM	Incubation Time:	20 h, 24 h	Result:	Inhibited proliferation of multiple cancer cell lines with IC ₅₀ value ranging from 1.08 to 3.45 μM, and had no effect on cell viability of GH4C1 cell.
Cell Line:	GH4C1 cell (48 h of serum deprivation)																
Concentration:	1 μM																
Incubation Time:	24 h																
Result:	Had no effect on cell viability of GH4C1 cell.																
Cell Line:	GH4C1 cell (FBS-starved GH4C1 cells treated with CXCL12 (25 nM) for 12 h)																
Concentration:	10 nM-1 μM																
Incubation Time:	20 h, 24 h																
Result:	Inhibited proliferation of multiple cancer cell lines with IC ₅₀ value ranging from 1.08 to 3.45 μM, and had no effect on cell viability of GH4C1 cell.																

Cell Line:	GH4C1 and GH4A11 cells (FBS-starved cells treated with CXCL12 (25 nM) for 48 h)
Concentration:	50 nM-1 μ M
Incubation Time:	12 h for GH4C1, 30 min for GH4A11
Result:	Reduced the number of migrating GH4C1 cells significantly, had no effect on GH4A11 cell (CRISPR-CAS9, reduction in CXCR4 mRNA) migration.

Western Blot Analysis^[1]

Cell Line:	GH4C1 cell (FBS-starved cells treated with CXCL12 (25 nM) for 15 min)
Concentration:	50 nM
Incubation Time:	30 min
Result:	Reduced ERK1/2 phosphorylation induced by CXCL12.

REFERENCES

[1]. Rosa Maria Vitale, et al. Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization. Bioorg Chem. 2020 Dec;105:104337.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA